Table 1.
Characteristics of migraine patients and subjects of the control group; there were no significant differences.
| Migraine with aura (n = 36) | Migraine without aura (n = 56) | Episodic migraine (n = 61) | Chronic migraine (n = 31) | Control (n = 24) | |
|---|---|---|---|---|---|
| Female sex (n, %) | 28 (78%) | 45 (80%) | 48 (79%) | 25 (81%) | 20 (83%) |
| Age, years (mean ± SD) | 33.2 (8.5) | 35.5 (9.1) | 33.5 (8.6) | 36.5 (9.3) | 32.8 (6.9) |
| Systolic blood pressure, mm Hg (mean ± SD) | 107.5 (11.4) | 106.7 (11.8) | 105.4 (10.7) | 110.2 (12.7) | 106.5 (13.5) |
| Diastolic blood pressure, mm Hg (mean ± SD) | 70.8 (8.5) | 69.2 (8.8) | 68.3 (8.1) | 72.9 (9.1) | 70.8 (8.3) |
| Body mass index, kg/m2 (mean ± SD) | 25.79 (2.64) | 25.51 (2.66) | 25.43 (2.68) | 25.99 (2.58) | 23 (5.6) |
| Glucose level, mmol/L (mean ± SD) | 5.0 (0.6) | 5.0 (0.5) | 4.9 (0.6) | 5.1 (0.5) | 5.2 (0.8) |
| Cholesterol level, mmol/L (mean ± SD) | 5.3 (0.6) | 5.2 (0.7) | 5.2 (0.7) | 5.2 (0.7) | 4.5 (1.2) |
| Family history of migraine (n, %) | 25 (69%) | 32 (57%) | 41 (67%) | 16(52%) | – |
|
Disease duration (years) (Me [Q25%; Q75%]) |
13 [8.5; 21.5] | 15.5 [10.5; 22.5] | 14 [6; 21] | 16 [11; 24] | – |
| Treatment | |||||
| Acute (during pain attacks) | |||||
| Triptanes | 17 (47%) | 29 (52%) | 32 (52%) | 14 (45%) | – |
| Nonsteroidal anti- Inflammatory drugs | 14 (39%) | 28(50%) | 26 (43%) | 16 (52%) | – |
| Other | 12 (33%) | 26 (46%) | 23 (38%) | 15 (48%) | – |
| Prophylactic | |||||
| Antidepressants | 13 (36%) | 24 (43%) | 22 (36%) | 15 (48%) | – |
| β-Blockers | 0 | 3 (5%) | 2 (3%) | 1 (3%) | – |
| Anticonvulsants | 0 | 6 (11%) | 2 (3%) | 4 (13%) | – |
| MRI findings | |||||
| WMH (n, %) | 16(44.4%) | 23 (41.0%) | 27 (44.2%) | 12 (38.7%) | – |
| Silent infarct-like lesions | – | – | – | – | – |
| Microbleeds | – | – | – | – | – |